Literature DB >> 28533724

Outline of the report on cardiovascular diseases in China, 2014.

Chen Weiwei1, Gao Runlin1, Liu Lisheng1, Zhu Manlu1, Wang Wen1, Wang Yongjun2, Wu Zhaosu3, Li Huijun1, Zheng Zhe1, Jiang Lixin1, Hu Shengshou1.   

Abstract

The risk factors for cardiovascular diseases (CVDs) are more prevalent in the Chinese population, and therefore, increase the incidence of CVD. In general, CVD morbidity and mortality will remain an upward trend in the next 10 years. Cardiovascular disease is the leading cause of death in China, which accounts for >40% of deaths from any cause. The burden of CVD is substantial and has become an important public health issue. Measures for the prevention and treatment of CVD in China should be further enforced without delay. Since 2005, the National Center for Cardiovascular Diseases has organized experts of cardiology, neurology, nephrology, diabetes, epidemiology, community health, health economics, biostatistics, and other related fields to compile the annual Report on Cardiovascular Diseases in China. The report aims to provide a timely review of the trend of the epidemic of CVD and to assess the progress of prevention and control of CVD. We present an abstract from the Report on Cardiovascular Diseases in China (2014), including trends in CVD, morbidity and mortality of major CVD, up-to-date assessment of risk factors, as well as health resources for CVD, and a profile of medical expenditure, with the aim of providing evidence for decision making in CVD prevention and control programmes in China, and of delivering the most authoritative information on CVD prevention and control for all citizens.

Entities:  

Keywords:  Cardiovascular diseases (CVD); Mortality; Prevalence; Risk factors

Year:  2016        PMID: 28533724     DOI: 10.1093/eurheartj/suw030

Source DB:  PubMed          Journal:  Eur Heart J Suppl        ISSN: 1520-765X            Impact factor:   1.803


  31 in total

1.  [Multicenter study of disease attributes in adult patients with pulmonary hypertension].

Authors:  Lin Dong; Jian-guo He; Zhi-hong Liu; Xian-ling Lu; Wei-jie Zeng; Yun-juan Sun; Xin-hai Ni; Qing Gu; Zhi-hui Zhao; Xian-sheng Cheng; Chang-ming Xiong
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2012-04-24

2.  Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).

Authors:  Shuiping Zhao; Yongjun Wang; Yiming Mu; Bilian Yu; Ping Ye; Xiaowei Yan; Zhanquan Li; Yidong Wei; Baishaili M Ambegaonakr; Dayi Hu
Journal:  Atherosclerosis       Date:  2014-06-05       Impact factor: 5.162

3.  [Prevalence and characteristic of overweight and obesity among adults in China, 2010].

Authors:  Xiao-yan Li; Yong Jiang; Nan Hu; Yi-chong Li; Mei Zhang; Zheng-jing Huang; Wen-hua Zhao
Journal:  Zhonghua Yu Fang Yi Xue Za Zhi       Date:  2012-08

4.  [Leisure-time physical activity and sedentary behaviors among Chinese adults in 2010].

Authors:  Xiao-rong Chen; Yong Jiang; Li-min Wang; Yi-chong Li; Mei Zhang; Nan Hu; Wen-hua Zhao
Journal:  Zhonghua Yu Fang Yi Xue Za Zhi       Date:  2012-05

5.  Prevalence and control of diabetes in Chinese adults.

Authors:  Yu Xu; Limin Wang; Jiang He; Yufang Bi; Mian Li; Tiange Wang; Linhong Wang; Yong Jiang; Meng Dai; Jieli Lu; Min Xu; Yichong Li; Nan Hu; Jianhong Li; Shengquan Mi; Chung-Shiuan Chen; Guangwei Li; Yiming Mu; Jiajun Zhao; Lingzhi Kong; Jialun Chen; Shenghan Lai; Weiqing Wang; Wenhua Zhao; Guang Ning
Journal:  JAMA       Date:  2013-09-04       Impact factor: 56.272

6.  ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.

Authors:  Jing Li; Xi Li; Qing Wang; Shuang Hu; Yongfei Wang; Frederick A Masoudi; John A Spertus; Harlan M Krumholz; Lixin Jiang
Journal:  Lancet       Date:  2014-06-23       Impact factor: 79.321

Review 7.  Sudden cardiac death in China.

Authors:  Shu Zhang
Journal:  Pacing Clin Electrophysiol       Date:  2009-09       Impact factor: 1.976

8.  Prevalence, awareness, treatment, and control of hypertension in elderly adults with chronic kidney disease: results from the survey of Prevalence, Awareness, and Treatment Rates in Chronic Kidney Disease Patients with Hypertension in China.

Authors:  Guangyan Cai; Ying Zheng; Xuefeng Sun; Xiangmei Chen
Journal:  J Am Geriatr Soc       Date:  2013-12       Impact factor: 5.562

9.  Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey.

Authors:  Jinwei Wang; Luxia Zhang; Fang Wang; Lisheng Liu; Haiyan Wang
Journal:  Am J Hypertens       Date:  2014-04-03       Impact factor: 2.689

Review 10.  COPD in China: the burden and importance of proper management.

Authors:  Xiaocong Fang; Xiangdong Wang; Chunxue Bai
Journal:  Chest       Date:  2011-04       Impact factor: 9.410

View more
  37 in total

1.  Serum Cortisol, 25 (OH)D, and Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus.

Authors:  Yuxi Jin; Dandan Wei; Pengling Liu; Fei Chen; Rongrong Li; Jinyu Zhang; Ruyi Zhang; Zuoxiang Liu; Wenqian Huo; Linlin Li; Chongjian Wang; Jinbao Ban; Zhenxing Mao
Journal:  Int J Endocrinol       Date:  2022-06-18       Impact factor: 2.803

2.  Association Between Serum Uric Acid Levels and Traditional Cardiovascular Risk Factors in Xiamen Residents of China: A Real-World Study.

Authors:  Peng Zhang; Linjian Chen; Zhaokai Li; Wei Ni; Lin Wang; Wanchun Mei; Guoqiang Ruan; Zaixing Shi; Cuilian Dai
Journal:  Front Cardiovasc Med       Date:  2022-05-17

Review 3.  Targeting Trimethylamine N-Oxide: A New Therapeutic Strategy for Alleviating Atherosclerosis.

Authors:  Lele Jing; Honghong Zhang; Qiannan Xiang; Liang Shen; Xiaoxia Guo; Changlin Zhai; Huilin Hu
Journal:  Front Cardiovasc Med       Date:  2022-06-13

4.  Development and Validation of a Prognostic Model to Predict High-Risk Patients for Coronary Heart Disease in Snorers With Uncontrolled Hypertension.

Authors:  Meng-Hui Wang; Mulalibieke Heizhati; Nan-Fang Li; Xiao-Guang Yao; Qin Luo; Meng-Yue Lin; Jing Hong; Yue Ma; Run Wang; Le Sun; Ying-Li Ren; Na Yue
Journal:  Front Cardiovasc Med       Date:  2022-04-21

5.  Clinical utility of the revised cardiac risk index in older Chinese patients with known coronary artery disease.

Authors:  Lu Che; Li Xu; Yuguang Huang; Chunhua Yu
Journal:  Clin Interv Aging       Date:  2017-12-22       Impact factor: 4.458

6.  Prediction of hypertension, hyperglycemia and dyslipidemia from retinal fundus photographs via deep learning: A cross-sectional study of chronic diseases in central China.

Authors:  Li Zhang; Mengya Yuan; Zhen An; Xiangmei Zhao; Hui Wu; Haibin Li; Ya Wang; Beibei Sun; Huijun Li; Shibin Ding; Xiang Zeng; Ling Chao; Pan Li; Weidong Wu
Journal:  PLoS One       Date:  2020-05-14       Impact factor: 3.240

7.  Adiponectin protects obesity-related glomerulopathy by inhibiting ROS/NF-κB/NLRP3 inflammation pathway.

Authors:  Xiaohong Xu; Xiaolin Huang; Liexiang Zhang; Xiaoli Huang; Zihan Qin; Fei Hua
Journal:  BMC Nephrol       Date:  2021-06-10       Impact factor: 2.388

Review 8.  Chinese Cardiovascular Disease Mobile Apps' Information Types, Information Quality, and Interactive Functions for Self-Management: Systematic Review.

Authors:  Bo Xie; Zhaohui Su; Wenhui Zhang; Run Cai
Journal:  JMIR Mhealth Uhealth       Date:  2017-12-14       Impact factor: 4.773

9.  6-Gingerol Activates PI3K/Akt and Inhibits Apoptosis to Attenuate Myocardial Ischemia/Reperfusion Injury.

Authors:  Xiangwei Lv; Tongtong Xu; Qi Wu; Yao Zhou; Guidong Huang; Yongnan Xu; Guoqiang Zhong
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-20       Impact factor: 2.629

10.  Survey of Antithrombotic Treatment in Rural Patients (>60 years) with Atrial Fibrillation in East China.

Authors:  Yong Wei; Juan Xu; Haiqing Wu; Genqing Zhou; Songwen Chen; Caihong Wang; Yahong Shen; Shunhong Yang; Bin Wang; Zheng He; Jianping Sun; Weidong Sun; Ping Ouyang; Shaowen Liu
Journal:  Sci Rep       Date:  2018-05-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.